Deguchi K, Suzuki Y, Ishihara R, Ishii Y, Nakazawa A, Matsumoto Y, Nishinari C, Nakane Y, Fukumoto T
Section of Studies, Tokyo Clinical Research Center.
Jpn J Antibiot. 1997 Jan;50(1):1-11.
In order to evaluate antimicrobial activity of arbekacin (ABK), coagulase-type and minimum inhibitory concentrations (MICs) of ABK and other drugs were determined against 700 strains of methicillin-resistant Staphylococcus aureus (MRSA) that were obtained in our laboratory from 1990 to 1996, 7 years. The results are summarized as follows; 1. The MIC-distributions of ABK against 100 strains of MRSA obtained yearly did not show stochastically significant differences. 2. The coagulase-type distributions showed differences over the years. Coagulase-type II strains increased and type IV strains decreased, and MIC-distributions of ABK and other drugs were different according to coagulase-types. 3. The detection frequencies of ABK-resistant strains (MIC of ABK: > or = 12.5 micrograms/ml) were 2.0 approximately 8.0% through the years. The frequency reported in 1980 was equal to the frequency obtained in 1992 approximately 1993 in a nationwide survey. Coagulase-types II, IV and VII that were ABK-resistant strains were frequently obtained, and most of ABK-resistant strains were also highly resistant to gentamicin.
为了评估阿贝卡星（ABK）的抗菌活性，测定了ABK及其他药物对1990年至1996年7年间从我们实验室获得的700株耐甲氧西林金黄色葡萄球菌（MRSA）的凝固酶类型和最低抑菌浓度（MIC）。结果总结如下：1. 每年获得的100株MRSA对ABK的MIC分布没有显示出随机显著差异。2. 凝固酶类型分布多年来存在差异。凝固酶II型菌株增加，IV型菌株减少，ABK和其他药物的MIC分布因凝固酶类型而异。3. 多年来，阿贝卡星耐药菌株（ABK的MIC：≥12.5微克/毫升）的检出频率为2.0%至8.0%左右。1980年报道的频率与1992年至1993年全国调查获得的频率相当。经常获得作为阿贝卡星耐药菌株的凝固酶II型、IV型和VII型，并且大多数阿贝卡星耐药菌株对庆大霉素也高度耐药。
